Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS627 vs. Pertuzumab in HER2+ breast cancer
NCT04514419Phase 3Active, not recruiting
- Sponsor
- BioRay Pharmaceutical
- Start
- Jun 2020
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of hs627 in breast cancer, sponsored by BioRay Pharmaceutical. Started Jun 2020; status: active, not recruiting.
02
Drugs
hs627
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04514419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04514419.